Oxlumo
| Chemical Name | lumasiran |
| Dosage Form | Injection (subcutaneous; 94.5 mg/0.5 mL |
| Drug Class | Oligonucleotides |
| System | Urinary |
| Company | Alnylam Pharmaceuticals Inc. |
| Approval Year | 2020 |
Indication
- For the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients.